EUCTR2006-006375-21-HU进行中（未招募）不适用
The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients with Type 1 Diabetes - COMPLETE T1D Trial
Eli Lilly and Company Ltd.0 个研究点目标入组 335 人开始时间: 2007年2月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Have type 1 diabetes based on the disease diagnostic criteria (World Health Organization [WHO] Classification, see Protocol Attachment IOOZ.2).
- •[2] Aged >=18 years.
- •[3] Duration of diabetes >=1 year.
- •[4] Have a hemoglobin A1c (HbA1c) 1.2 to 2.0 times the upper limit of the normal (ULN) reference range within 30 days prior to Visit 1 or collected and analyzed at a local laboratory at Visit 1.
- •[5] Body mass index (BMI) <=35 kg/m2.
- •[6] As determined by the investigator, are capable and willing to do the following:
- •perform self monitoring of blood glucose (SMBG),
- •complete patient diaries as required for this protocol,
- •use the insulin injection device(s) according to the instructions provided,
- •are receptive to diabetes education,
- •comply with the required study visits.
- •[7] Have given written informed consent to participate in this study in accordance with local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •9] Are taking any oral antihyperglycemic medications (OAMs).
- •[10] Have had more than one episode of severe hypoglycemia, as defined in the Abbreviations and Definitions section of the protocol, within 6 months prior to entry into the study.
- •[11] Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.
- •[12] Women who are breastfeeding.
- •[13] Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease.
- •[14] Have a history of renal transplantation or are currently receiving renal dialysis or creatinine greater than 2.0 mg/dL (177 µmol/L).
- •[15] Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease (alanine transaminase [ALT], or aspartate transaminase [AST] greater than 2 times the upper limit of the reference range, as defined by the local laboratory) or have albumin value above or below the normal reference range, as defined by the local laboratory.
- •[16] Are undergoing therapy for a malignancy other than basal cell or squamous cell skin cancer.
- •[17] Have known hypersensitivity or allergy to any of the study insulins or excipients of the study insulins.
- •[18] Have had a blood transfusion or severe blood loss within 3 months prior to Visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
- •[19] Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding Visit 1.
- •[20] Have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night).
- •[21] Have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the protocol.
- •[22] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[23] Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •[24] Are Lilly employees.
- •[25] Have previously completed or withdrawn from this study after having signed the informed consent document.
研究者
相似试验
进行中（未招募）
1 期
The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients with Type 1 Diabetes - COMPLETE T1D TrialMedDRA version: 8.1Level: LLTClassification code 10045228Term: Type I diabetes mellitustype 1 diabetesEUCTR2006-006375-21-GREli Lilly and Company Ltd.356
进行中（未招募）
不适用
The COMPLETE T2D Trial: COMParison of Insulin Lipsro Protamine Suspension and DETEmir in Type 2 Diabetes Mellitus: Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal Therapy for Patients with Type 2 Diabetes Mellitus - COMPLETE T2D Trialtype 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-002150-39-HUEli Lilly and Company Ltd.378
进行中（未招募）
不适用
The PRIME T2D Trial: Prandial-basal Insulin Regimens to Improve MEaltime Glycemia in Type 2 DiabetesComparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture with Separate Basal and Bolus Insulin Injections - IOOXEUCTR2006-002519-28-GREli Lilly and Company Ltd.500
已完成
不适用
Intensive versus conventional insulin therapy for inpatient medical patients [Insulinoterapia intensificada versus terapia habitual en pacientes hospitalizados por patología médica]HyperglycaemiaSigns and SymptomsElevated blood glucose levelISRCTN55845280ational Fund of Investigation and Development in Health (Fondo nacional de investigación y desarrollo en salud [FONIS]) (Chile)250
已完成
不适用
Comparison of two regimens of Insulin and Insulin-Metformin in glycemic control of type 2 Diabetic patients after CABG surgeryType 2 diabetes.Non-insulin dependent diabetesIRCT201008084365N5Mazandaran University of Medical Sciences100